Quarterly ResultAug 6, 2026, 07:38 AM
Collegium Q2 Revenue $199.9M; Updates 2026 Guidance
AI Summary
Collegium Pharmaceutical reported Q2 2026 net revenues of $199.9 million, a 6% increase year-over-year, driven by strong demand in its ADHD portfolio, including JORNAY PM and the newly acquired AZSTARYS. The company completed the acquisition of AZSTARYS in May, which contributed $12.9 million in partial-quarter net revenue. However, the company updated its full-year 2026 financial guidance, lowering projections for Product Revenues, Net, and Adjusted EBITDA, primarily due to lower-than-expected revenue from the Nucynta authorized generic versions.
Key Highlights
- Q2 2026 Net Revenues were $199.9 million, a 6% increase year-over-year.
- JORNAY PM net revenue grew 41% year-over-year to $46.1 million in Q2 2026.
- AZSTARYS generated $12.9 million in net revenue for a partial quarter after May acquisition.
- Pain portfolio net revenues were $140.9 million, down 9% year-over-year.
- Updated full-year 2026 Product Revenues, Net guidance to $825-$855 million.
- Updated full-year 2026 Adjusted EBITDA guidance to $445-$470 million.
- Reported a GAAP net loss of ($15.1) million for Q2 2026.
- Adjusted EBITDA for Q2 2026 was $113.8 million, an 8% increase year-over-year.
Price Impact
More from COLL